Showing 4251-4260 of 6977 results for "".
- Exuviance Introduces HA100 Micro-Filler Regimenhttps://practicaldermatology.com/news/exuviance-introduces-ha100-micro-filler-regimen/2457502/Exuviance is launching HA100 Micro-Filler Regimen, a two-step beauty regimen featuring new Micro-Cone Patches that delivers 1
- Case Study: Allergy Shots May Treat Severe Eczemahttps://practicaldermatology.com/news/case-study-allergy-shots-may-treat-severe-eczema/2457503/Allergy shots provided significant benefits to the eczema symptoms of a 48-year-old man, according to challenging case presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Seattle. “The man had suffered with severe eczema since chi
- Study: Novel 1060nm Diode Laser Is Safe and Effective for Hair Removalhttps://practicaldermatology.com/news/study-novel-1060-diode-laser-is-safe-and-effective-for-hair-removal/2457510/A novel 1060 nm diode laser system is safe and effective for hair removal and long-term hair reduction in all skin types including darkly pigmented individuals, according to research in Lasers in Surgery and Medicine (LSM)
- Endo's CCH Improves Appearance of Cellulite in Buttockshttps://practicaldermatology.com/news/endos-cch-improves-appearance-of-cellulite-in-buttocks/2457516/Endo International plc’s clostridium histolyticum (CCH) performed well in two identical Phase 3 studies for the treatment of cellulite in the buttocks. Subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment,
- Endocannabinoids Effective in Lupus Modelhttps://practicaldermatology.com/news/endocannabinoids-effective-in-lupus-model/2457521/Zylö Therapeutics’ patented Nanopod™ aerogel delivery technology was used to demonstrate the efficacy of endocannabinoids in a model of cutaneous lupus in a study presented last month at the meeting of the American College of Rheumatology. There is growing evidence that t
- Cooling Caps and Other Cooling Methods May Prevent Taxane-Induced Dermatologic Eventshttps://practicaldermatology.com/news/cooling-caps-and-other-cooling-methods-may-prevent-taxane-induced-dermatologic-events/2457523/Cooling therapies such as cold caps, scalp cooling systems, frozen gloves, and frozen socks may offer the best protection against the adverse effects of taxane-based chemotherapy, according to a new study in JAMA Dermatology. “Taxanes induce dermatologic changes through dir
- New AD Estimate: As Many As 16.5 Million Adults Have ADhttps://practicaldermatology.com/news/new-ad-estimate-as-many-as-165-million-adults-have-ad/2457524/As many as 16.5 million adults in America have atopic dermatitis (AD). This estimate comes from a new study from the Perelman School of Medicine at the University of Pennsylvania, which also projected 6.6 million of these adults have disease that wo
- Scott Peterson, PhD to Head Medical Affairs at Evolushttps://practicaldermatology.com/news/scott-peterson-phd-to-head-medical-affairs-at-evolus/2457535/R. Scott Peterson, PhD is now Head of Medical Affairs at Evolus, supporting the strategic development and execution of medical affairs initiatives. Evolus is a company dedicated to aestheti
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europehttps://practicaldermatology.com/news/amgevita-amgens-biosimilar-adalimumab-launches-in-europe/2457555/Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC) and is authorized for the treatment of inflammatory diseases in adults, including moder